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Abstract
Background:  Attention Deficit Hyperactivity Disorder (ADHD) is a common childhood
psychiatric disorder. The management of ADHD has recently been highlighted. The National
Institute of Clinical Excellence (NICE) and Scottish Intercollegiate Guidelines network (SIGN) have
both produced management guidelines. Doctors working within Primary Care in countries such as
the United States play an important role in the management of ADHD. In the United Kingdom
however the role of doctors in primary care in the management of ADHD, both individually and
within shared care protocols, is only now being identified and defined. Is this role for Primary Care
likely to be acceptable and effective?
Discussion: There is some evidence that doctors working within Primary Care in the United
Kingdom are willing to follow up children on medication for ADHD and carry out monitoring of
physical status. However many feel unconfident in the management of ADHD and most have
received little or no training in child psychiatry. There are also concerns that adverse media reports
will have an undue influence on the attitudes of doctors within primary care to families with
children suffering from ADHD.
Summary: There are important barriers to be tackled before shared care protocols for ADHD
can be successfully implemented in the United Kingdom. Tailored information about ADHD needs
to be provided to doctors in primary care. Clear dialogue between planners and healthcare
professionals from both primary and secondary care is essential to ensure that service delivery is
acceptable to healthcare providers, tailored to their skills and is adequately resourced.
Background
Attention Deficit Hyperactivity Disorder (ADHD), known
as Hyperkinetic Disorder under the ICD-10 classificatory
system, is a common disorder that affects between 1.5%
and 6% of children [1,2]. The disorder is an early onset
condition that is associated with educational failure, so-
cial difficulties and an increased risk of antisocial behav-
iour and problems in adult life including substance
misuse and criminality [1]. ADHD now represents the
commonest reason for follow up in child and adolescent
psychiatry clinics [2] and an average general practitioner
can expect to have between two and four children receiv-
ing treatment for it on their list. Nevertheless there is evi-
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dence that most children who fulfil diagnostic criteria
remain undetected in the general population [3].
The treatment of ADHD has been the focus of extensive re-
view and several authoritative reports and recommenda-
tions have been recently circulated [4–8]. These
recommendations support the use of stimulant medica-
tion (such as methylphenidate (Ritalin, Equasym) and
dexamphetamine (dexedrine)) as first line treatment (ei-
ther alone or in combination with non-pharmacological
interventions including behaviour therapy) for children
with accurately diagnosed ADHD [4–9]. Moreover the
high level of under treatment has also been highlighted in
the recent National Institute of Clinical Excellence (NICE)
guidance on the use of methylphenidate in ADHD [4].
Discussion
Current recommendations are that medication should be
initiated by child and adolescent psychiatrists or paedia-
tricians or learning disability specialists with particular ex-
pertise [4,5]. Once the condition is stabilised children can
then be followed up in primary care [4,5] and NICE guid-
ance recommends health authorities should draw up
shared care protocols [4] . Is primary care in this country
ready to follow these recommendations? Follow up of
ADHD is often undertaken by primary care in the Unites
States [8,10]. Moreover adult ADHD is becoming increas-
ingly recognised and some of the cohort of children and
adolescents who are currently on stimulant medication
will graduate to adult mental health services. These factors
together with statements in the NICE guidance on the use
of methylphenidate are likely to increase pressure on pri-
mary care to become more involved in the management
of ADHD.
However there is a great need for caution and careful plan-
ning before implementing shared care protocols for
ADHD and sharing follow up with primary care. Primary
care teams are already having to assume responsibility for
follow up of an increasing number of chronic conditions
and although for some (such as diabetes) there is evidence
this is successful [11], the monitoring of children on treat-
ment for ADHD may pose different problems. Most gen-
eral practitioners and nurses will have undergone no or
very little training in child and adolescent psychiatry.
Many general practitioners do not feel confident about
their skills in recognising and undertaking follow-up
management of ADHD and feel that education is essential
[12]. Attitudes amongst members of the primary care
team members may also represent a problem. The media
represents an important source of knowledge of ADHD
for many general practitioners [12]. Given that recent me-
dia features have highlighted problems with over diagno-
sis and over treatment this is likely to affect attitudes
within the primary care team to the use of stimulant med-
ication and heighten anxieties about management. Al-
though there is some evidence that most general
practitioners are willing to take on physical monitoring of
children on medication for ADHD (e.g. height, weight
and blood tests if necessary) the only available data sug-
gest general practitioners feel clinical monitoring of these
children is a specialist responsibility [12]. Therefore
shared care protocols for ADHD may have limited impact
in reducing specialist workload and will need to incorpo-
rate effective mechanisms for close integration and good
communication between services to ensure that patients
and their families receive appropriate care.
It is therefore important that a clear strategy for the follow
up care of children with ADHD is devised. Planners need
to ensure that roles and responsibilities of different
healthcare sectors in monitoring children with ADHD on
medication are clearly demarcated and acceptable to the
professionals concerned. When these clear roles have
been identified, it is then important to ensure that profes-
sionals possess the appropriate skills and knowledge to ef-
fectively undertake the assigned role. The resource
implications of carrying out this monitoring also need to
be addressed so that this can be done successfully (as has
been achieved for monitoring of anticoagulant therapy).
It is essential that patient needs are met in a coordinated
and supported manner to avoid a situation of placing chil-
dren and families into a "no mans land" of uncertain re-
sponsibility and inadequate skills,
Summary
ADHD is likely to become increasingly important for pri-
mary care. To ensure that patient care is not compromised
by the introduction of shared care protocols it is impor-
tant that there is a clear dialogue between planners and
healthcare professionals from both primary and second-
ary care. This is necessary to ensure mechanisms are in
place for this care to be undertaken effectively and proper-
ly organised. Service delivery needs to be sensitive to pa-
tient need, acceptable to healthcare providers and tailored
to their skills and finally must be adequately resourced.
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